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THE THESIS EXPLAINED 
The biological issue: 
Prostate cancer (PCa) is initially treated with removal of androgens; 
however, androgen depletion is usually associated with the 
recurrence of the metastatic and more aggressive PCa termed 
castration-resistant prostate cancer (1). Small cell neuroendocrine 
carcinoma (SCNC), an extremely aggressive variant form of 
prostate cancer that contain all neuroendocrine (NE) cells, are often 
seen as recurrent tumors in patients with a history of 
adenocarcinoma and treated with hormonal therapy (2). NE cells are 
hormone-insensitive cells and express selectively the putative 
prostate cancer stem cell (CSC) marker CD44 (3). Our group 
has previously demonstrated that Toll-Like receptor 3 (TLR3) 
agonist poly (I:C), that mimics viral genome, induces apoptosis in 
the androgen-dependent PCa cell line LNCaP, that resemble 
prostatic adenocarcinoma, in vitro (4) and in vivo (5).  
On the contrary, only a weak apoptotic effect is observed in the more 
aggressive and androgen-independent PCa cells PC3 and DU-145 
(6), the prototype of SCNC composed by neuroendocrine highly 
aggressive cells.  
It has been recently reported that stimulation of TLR3 by poly (I:C) 
promotes breast cancer cells toward a CSC phenotype in vitro and 
in vivo, evaluated as CD44high/CD24-negative expression (7). To 
ascertain if poly (I:C) treatment is able to select or to target CSCs, 
in this study we intend to determine whether the apoptosis resistance 
to poly (I:C) can be correlated to CD44 expression in the androgen 
independent PCa cell lines PC3 and DU-145. 
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Results: 
 
Unexpectedly, we found very small CD44-negative cells, resistant 
to poly (I:C), that gave rise to a CD44-positive population in PC3 
cells after just 48 hours of culture post sorting. The same rate of 
conversion was observed in the 2-4% of sorted CD44-negative very 
small in size cells contained in parental PC3 and DU-145 cells.  
In addition, CD44-negative-sorted PC3 cells converted in CD44high 
cells, expanded in vitro culture, displayed an higher clonogenic 
potential than sorted CD44high -derived population, probably  
because they produced mainly holoclones, described to be enriched 
in stem-like cells, whereas CD44high population generated mainly 
meroclones, a mixture of cells of different proliferative potential.  
Moreover, in secondary clonogenic assay, the clones generated by 
CD44-negative-sorted cells exhibited a significantly higher 
clonogenic potential than clones derived by CD44high -sorted 
population. All types of the CD44high and CD44-negative-derived 
clones became positive for CD44 suggesting that this molecule is 
probably expressed in both cancer stem, progenitor and more 
differentiated cells.  
Although our data indicate that the cellular population generated by 
CD44-negative-sorted cells were indistinguishable from the 
CD44high -derived cells in terms of CD44 expression, we found that 
CD44 transcript variant 3, containing variant exons v8–v10, was 
more highly expressed in the population generated by CD44- 
negative-sorted cells at the mRNA and protein level in both the 
androgen-independent cell lines PC3 and DU-145.  
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Conclusions: 
It is becoming apparent that characterization of prostate cancer stem 
cells (CSCs) should be based not only on cell surface markers 
because they are often subjected to dynamic expression changes. 
Our data are in accordance with this theory because we 
demonstrated that CD44high cells, described to be stem-like and more 
tumorigenic in prostate cancer, may arise from a CD44-negative 
population, displaying functional stem-like traits, enriched 
following poly (I:C) and docetaxel, the canonical 
chemotherapeutical treatment of PCa. 
Moreover CD44-negative population isolated from PC3 and DU-
145 cells, enriched of self-renewing cells, re-expressed specifically 
CD44 v8-v10 splice variant isoform. Given that many CD44v 
isoforms are preferentially expressed on cancer cells and involved 
in tumor progression, the identification of new CD44v isoforms in 
CSCs will open new field of investigation to find innovative targeted 
therapies against CSCs in PCa. To conclude, our data, support the 
concept that, under certain conditions, some tumors exhibit 
plasticity by reversibly transitioning between a stem and non-stem-
cell state expressing microenvironment-dependent variable markers. 
Of note, the therapeutic potential of TLR3 agonist on prostate 
cancer, shown by us and others groups, should be carefully 
evaluated with consideration of its possible role in mediating nuclear 
reprogramming in the induction of pluripotency in embryonic 
fibroblasts (8) and CSC phenotypes (7) thus potentiating cancer 
recurrences, as demonstrated in breast cancer.  
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1. INTRODUCTION
1.1 Prostatic carcinoma 
Prostate cancer (PCa) is the most common  malignancy in men and 
the second leading cause of cancer-related deaths (9).  
PCa develops over a long period of time from normal prostate to 
prostatic intraepithelial neoplasia (PIN) then to early- and late-stage 
PCa and finally to metastatic PCa (10). If localized, PCa can be 
cured by radical prostatectomy or irradiation. However, more than 
30% of patients may relapse after surgery (11).  
Although early detection through serum testing for prostate specific 
antigen (PSA) has significantly reduced the number of fatalities, its 
widespread use has caused overdiagnosis and overtreatment of PCa 
diagnosed during an indolent phase that could be avoided by using 
an active surveillance. On the contrary, use of PSA alone as a 
decision-point for identifying prostate biopsy can also lead to 
underdiagnosis or non-diagnosis of cancers that are histologically-
aggressive but have PSA levels below routine thresholds (12). 
Therefore, in order to improve prostate cancer detection, decision-
making and care, much research has needed to discern aggressive 
from indolent PCa.  
Advanced PCa is mainly treated with androgen-deprivation therapy 
(ADT), but it is widely accepted that androgen ablation  can promote 
the progression of the tumor to the castration resistant stage (1).  
Both castration resistant prostate cancer (CRPC) and primary PCa 
are able to metastasize to various organs such as the bone, lung and 
liver. Once metastasis occurs the disease becomes incurable (13). 
Over 95% of prostate tumors are adenocarcinomas that arise from 
the epithelia of the prostatic gland composed of three differentiated 
epithelial cell types: luminal, basal and neuroendocrine (NE) cells 
that are scattered throughout the prostate constituting ˜1% of the 
total epithelial cell population. The luminal cells secrete proteins 
including PSA and express high levels of androgen receptor (AR) 
and low molecular weight keratins (cytokeratins 8 and 18). 
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Basal cells, in contrast to luminal cells which depend on androgens 
for survival, do not express AR and are androgen-independent. The 
basal layer is characterized by the expression of p63, basal keratins 
(cytokeratins 5 and 14) and integrins (α6β4, α3β1). Additionally, NE 
cells express endocrine markers such as chromogranin A and 
synaptophysin and are AR-negative.  
Prostatic adenocarcinomas are characterized by a loss of basal cells, 
reduced matrix diversity and uncontrolled proliferation of malignant 
tumor cells with features of luminal differentiation including the 
expression of AR and PSA (Figure I).  
 Frontiers in Oncology (2013) 3:273 
Figure I. Prostate epithelial gland structure in normal and tumor conditions. 
The normal prostate epithelium is composed of  basal cells, luminal and rare NE 
cells that express specific markers. Prostate tumor is characterized by 
uncontrolled proliferation of luminal cells and a loss of basal cells. 
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However, tumor cells also express basal integrins and often co-
express basal and luminal keratins, such as cytokeratins 5 and 8  
that are restricted to their distinct cell types in normal tissue (14;15). 
The presence of “intermediate cells” that co-express luminal and 
basal markers sustains the hypothesis that PCa develops from the 
disruption of differentiation pathways which normally restrict basal 
and luminal marker expression to their respective cell types. The 
cell of origin, defined as the cell type within a normal tissue that 
undergoes oncogenic transformation giving rise to the tumor, has 
not been clearly identified in PCa. 
The classic androgen ablation and replacement experiment 
demonstrates the presence of prostate stem/progenitor cells within 
the basal layer. Androgen withdrawal leads to apoptosis of the 
luminal cells and the survival of the basal cells. In the adult prostate, 
luminal cells are regularly shed and replaced through differentiation 
(16).  
A simplistic view of this observation is that a basal progenitor or 
stem cell gives rise to both basal and luminal populations through a 
transient differentiation process (17;18). However, findings from 
mouse models support the idea that there are at least three different 
prostate epithelial progenitor populations (basal, luminal and 
bipotent progenitors), but which ones initiate PCa still remains 
unresolved (19-21). Several studies demonstrate either basal or 
luminal progenitors can be the initiating cancer cell (22;23). 
Better understanding of prostate differentiation will be required to 
identify the cell of origin in PCa. 
Adenocarcinoma cells, like the normal prostatic gland, rely on 
androgens for their development and progression and contain rare 
quiescent androgen-independent NE cells. This is the basis for the 
use of androgen-deprivation therapy for patients with advanced and 
recurrent diseases (24). This treatment rarely eradicate all prostate 
cancer cell populations inducing apoptosis of the androgen-
dependent luminal tumor cells and an increase in NE cells that, 
through their secreted products, can promote androgen-independent 
growth of prostate cancer cells contributing to the progression of the 
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tumor to the castration resistant stage. Small cell neuroendocrine 
carcinoma (SCNC) in which the tumor cells are all NE cells highly 
aggressive, are often seen as recurrent tumors in patients with a 
history of adenocarcinoma and treated with hormonal therapy (2). 
Only 1 to 2% of prostate cancers are diagnosed originally as 
neuroendocrine prostate tumors. These tumors can  be pure or 
admixed with prostatic adenocarcinomas. SCNC is defined as a 
poorly differentiated NE cancer characterized by NE tumor cells 
highly proliferative, metastatic, and resistant to most conventional 
therapies. To date, the origin of these tumors remains uncertain. 
Mounting evidence support the idea that NE-like tumor cells could 
transdifferentiate from adenocarcinoma in response to treatment. 
Accumulation of new genetic alterations such as RB loss, AURKA, 
and MYCN amplifications may promote rapid cell expansion and 
subsequent emergence of a prevailing NE component in the form of 
small-cell carcinoma that rapidly proliferates. Adenocarcinoma and 
small-cell carcinoma components may also derive from 
transformation of a common multipotential prostatic progenitor that 
accumulated molecular alterations driving epithelial or NE 
phenotypes (25). In fact, NE cells have some features of cancer stem 
cells (CSCs), such as the expression of CD44 and CD133 (3;26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chiara Di Stefano 
11 
1.2 Tumor heterogeneity 
The highly heterogeneous nature of prostate cancer poses many 
obstacles to therapy. 
PCa striking cellular heterogeneity can give rise to therapeutic 
resistance and disease progression.  
There are different theories to explain the origin of tumor cellular 
heterogeneity. In the stochastic model, tumor cells have a random 
probability of developing mutations to permit tumor maintenance 
and progression. It is becoming increasingly clear that a tumor does 
not have one single tumor genome, but consists of multiple genomes 
that belong to distinct subclones. Under selective pressures, such as 
chemo- or radiotherapy, clones that have acquired resistant 
properties survive and give rise again to a heterogeneous population. 
These subclones may evolve in parallel over the lifetime of a cancer 
and contribute to intratumoral heterogeneity. However, even within 
single genetic subclones, the cells behave differently: some cells 
retain self-renewal capacity and long-term clonal maintenance and 
most tumor cells are postmitotic and destined for clearance (Figure 
II)
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                                           Cell Stem Cell (2014)  14(3): 275–91 
 
 Figure II. Functional diversity within single genetic subclones. 
        Single genetic subclones (illustrated by different colors) are 
        characterized by a mixture of cells with different proliferative 
        potentials. Chemotherapy spares the relatively dormant cells that, 
        following therapy, can seed a new cancer. 
        Subclonal diversity can be altered with chemotherapy that can 
        introduce new genetic mutations to confer treatment resistance. 
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The cancer stem cell (CSC) model in which sustained tumor growth 
is restricted to selected subpopulations called cancer stem cells, is  
based upon the hypothesis that tumors, like adult tissues, originate 
from cells that can self-renew and give rise to more differentiated 
progeny that comprises the bulk of the tumor (27). Tumor 
heterogeneity, consisting of genetic and phenotypic diversity, is thus 
referable to a hierarchy of differentiation that includes CSCs. Both 
these hypothesis tend to identify a single cell population as the 
therapeutic target: the prevailing clone over time in the first case and 
the CSC in the latter.  
Although the initial hierarchical theory for existence of cancer stem 
cells assumed a stable population that always give rise to progeny 
cells lacking, or reduced for, the tumor initiating property, is 
emerging that, some tumors, under certain conditions, exhibit 
plasticity by reversibly shifting between stem-like and more 
committed cells.  
The notion that there are multiple hierarchies guided by similar but 
not identical CSCs in a tumor might help explain the highly complex 
nature of intratumoral heterogeneity and resistance to targeted 
therapies. Then integration of the CSC model with the stochastic 
model may be necessary (28) (Fig. III). 
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                           Modified by  Stem Cells (2016)  34(8): 1997-2007 
 
Figure III. Cancer stem cell model integrated with the stochastic model. 
The cancer stem cell theory focuses on the internal heterogeneity within 
individual clonal subpopulations of a tumor due to a hierarchy of differentiation. 
The stochastic model allow the clonal outgrowth of novel cell populations arising 
from the acquisition of accumulating mutations.  
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1.3 Prostate cancer stem cells: markers and methods for their 
enrichment 
The cancer stem cell model represents a rebirth of an old idea. In the 
early 1858 Rudolf Virchow proposed that cancers arise from 
embryonic-like tissue noting the histologic similarities between 
developing normal tissues and poorly differentiated cancers such as 
teratocarcinomas. Although this concept is not new, the first 
experimental evidence for the actual existence of CSCs came from 
hematological malignancies in 1997 (29). Subsequently, the 
existence of  CSCs has been identified in different solid tumors such 
as breast cancer (30), gliomas (31), lung cancer (32), colon cancer 
(33;34) and prostate cancer (35). 
CSCs have been identified by developing new culture methods and 
functional assays to enrich a subpopulation with self-renewal ability 
in vitro and tumor initiating and propagating ability in vivo. Prostate 
cancer stem cells (PCSCs) can be enriched by selecting cells that 
have the ability to efflux Hoechst dye (36), to form prostatespheres 
in a serum-free suspension culture system (37) or by sorting cells 
that exhibit high levels of ALDH activity (38). Most of PCSCs have 
been isolated by using cell surface markers such as CD24, CD44 
(39), CD49f (40), CD133 (26;35), CD166 (41) and α2β1 integrins 
(35). Those markers have been tested alone and in several 
combinations but there is currently no universally accepted 
collection of CSC markers for isolation of a “pure” population of 
PCSCs which could clearly lead in the all cases to distinct cancer 
stem cells. The cause of this situation is the considerable diversity 
in the tumor histotypes and their genetic heterogeneity.  
Several studies demonstrate the utility of CD133 as an enrichment 
marker for cells with stem-like properties. Collins et al. used CD133 
marker to identify the prostate cancer stem cell population with a 
CD44+ / α2β1high / CD133+ phenotype characterized by a significant 
capacity for self-renewal. On the other hand, a large body of 
evidence narrows down its use as a stem cell marker. Although 
CD133-positive glioma cells were initially considered to be CSCs 
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(31), many proofs support the existence of CD133-negative glioma 
stem cells able to initiate tumors as well as generate CD133-positive 
progeny (42). 
Patralawa and coworkers, in one of the studies performed in vitro 
and in vivo on cell lines and xenograft tumor models, showed that 
CD44-positive (CD44+) PCa cells are more tumorigenic and 
metastatic than the corresponding CD44-negative (CD44-) PCa 
cells and possess many intrinsic traits of tumor progenitors (39). On 
the other hand, they also observed tumor development in CD44- PCa 
cells and clonal analyses revealed the emergence of the CD44+ 
clones from the pure CD44- cell population. It has, therefore, been 
proposed that characterization of CSCs be based not only on cell 
surface markers that are often subjected to dynamic expression 
changes.  
The formation of holoclones has been adopted as a surrogate stem 
cell assay especially in the study of prostate cancer. An increased 
number of holoclones is considered as enrichment for CSCs. The 
existence of a cellular hierarchy reflecting the differentiation and 
proliferative capacities of stem cells within normal tissue was first 
characterized over 20 years ago (43). Using primary cultures of 
human keratinocytes, the Authors found that single cells gave rise 
to 3 types of clones classified as holoclones, meroclones and 
paraclones with different proliferative capacities. These colonies are 
believed to be derived respectively from stem, transit-amplifying 
cells and differentiated cells. It has since been shown that the 
existence of a stem cell hierarchy persists in cancer cell lines, 
including prostate cancer (44). 
The PC3 prostate cancer cell line was shown to contain an highly 
heterogeneous cell population of holoclones, meroclones and 
paraclones. Li and colleagues demonstrated that, like keratinocytes  
holoclones, PC3-derived holoclones contained self-renewing stem-
like cells and were enriched for expression of the stem cell markers 
CD44 and α2β1 integrin. (44). 
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1.4 CD44 and its splicing variants: molecular structure and 
functions 
The hyaluronic acid receptor CD44 is a single pass transmembrane 
glycoprotein involved in cell-cell and cell-matrix adhesion and in 
cell signaling. It has a relevant role in lymphocyte homing, 
inflammation, cell migration, signaling and tumor metastasis 
(45;46).  
CD44 is encoded by the highly conserved CD44 gene located on 
chromosome 11 in humans (47).  
Alternative splicing of 9 out of 19 exons in human CD44 pre-mRNA 
results in expression of different transcript variants (CD44v 
isoforms), leading to variation in the length and function of the 
extracellular domain (Figure IV A). The predominant form of CD44, 
expressed on most vertebrate cells, is named standard isoform 
(CD44s) and is translated to a polypeptide of 85-95 kD from exons 
1-5 joined to exons 15-19. Most noticeable, CD44v isoforms are 
expressed in a broad range of cancers especially those in advanced 
stages (48).  
CD44 protein contains three functional domains: an extracellular 
domain (or ectodomain), a transmembrane (TM) domain and an 
intracellular domain (ICD) (47) (Figure IV B). The N-terminal 
domain, encoded by the first five exons of CD44, acts as ligand-
binding receptor for the main ligand hyaluronan (46) and also for 
extracellular matrix (ECM) proteins such as osteopontin (49), 
collagen, laminin (50), and fibronectin (51).  
The introduction of new exons in the extracellular domain 
modulates HA-binding affinity by inducing conformational changes 
or providing CD44 isoforms to have new functions as a coreceptor 
by producing new binding sites for many growth factors and 
receptors (52).  
The transmembrane domain is responsible for lymphocyte homing 
and mediates CD44 activation signaling by coupling CD44/CD44v 
to cofactors, adaptor proteins, receptor tyrosine kinases, or non-
receptor protein-tyrosine kinases (53).  
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CD44 ICD has also a pivotal role for the function of CD44 in 
signaling transduction. CD44 undergoes sequential proteolytic 
cleavages in the extracellular domain, mediated by membrane-
associated metalloproteases (MMPs), and transmembrane domain. 
The first cleavage produces a soluble fragment released into the 
culture supernatant (soluble CD44) and a membrane-bound product 
(CD44 EXT, CD44 extracellular truncation).  
Then, CD44 EXT is cleaved by the presenilin-γ-secretase, resulting 
in the release of a CD44 intracellular domain (CD44 ICD) into 
cytoplasm that translocates into the nucleus where it can 
transcriptionally regulate the expression of target genes such as 
CD44 itself, thus promoting the rapid turnover of CD44 that is 
required for efficient cell migration (54).  
Therefore, the sequential proteolytic cleavage is crucial for CD44-
mediated signaling pathway.  
The cytoplasmic tail of CD44 is anchored to the actin cytoskeleton 
and to ezrin and ankyrin with functions involved not only in cell 
migration but also in signal transduction of CD44 (55). 
Furthermore, the complexity of the CD44 protein family and 
functions is increased by various degrees of post-translational 
modifications such as N- and O-linked glycosylation and 
glycosaminoglycanation.   
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   Proc Natl Acad Sci (2015)  112(50): 15444–9 
Figure IV. Model of CD44 exon organization.  
(A) CD44 contains constant exons that are inserted in all CD44 transcripts and 
proteins and variant exons (pink circles) selected by alternative splicing in various 
combinations to encode CD44 variant proteins.  
Exon 18 encodes an alternatively spliced short form that spliced out in most CD44 
isoforms. The black circles represent the ectodomain, in dark blue is illustrated 
the intracellular domain. The HA binding domain and the transmembrane domain 
are respectively depicted by green and light blue circles.   
(B) Schematic representation of CD44 protein domains: the variant exons (pink) 
are inserted into a single site within the membrane proximal region of the 
ectodomain close to the transmembrane (TM) domain linked to the intracellular 
domain. 
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1.5  CD44 standard (CD44s) and CD44 variant (CD44v) 
isoforms as putative CSCs markers  
 
Most human cancers, as well as prostate cancer, are characterized 
by dysregulated CD44 expression. PCa loses expression of CD44s 
(56), a marker of basal cells in benign epithelium, and overexpresses 
splice variant isoforms. CD44, especially CD44v isoforms have 
been identified as CSC markers and critical players in regulating 
tumor progression, metastases and treatment resistance in many 
cancers. 
A significant reduction of CD44s expression in proportion to tumor 
grade was first described in 1996: CD44s resulted decreased in 
metastatic cancer compared to matched primary cancer (57). It was 
later found that patient-derived cancers had increased CD44 v7-v10 
messenger RNA and knock-down of this variant isoform by RNAi 
significantly decreased invasion and migration (58). 
Currently, Ni J. and colleagues have demonstrated high levels of 
CD44 v6 in primary prostate cancer tissues and lymph node 
metastases including cancer cells and surrounding stromal cells but 
not in normal prostate tissues. On the other hand, CD44s expression 
is negative in all primary prostate cancer tissues and lymph node 
metastases, while is strongly positive in all normal prostate tissues 
suggesting that CD44s may negatively regulate CaP progression 
while CD44 v6 may be involved in CaP progression and metastases. 
Finally, the authors demonstrated that CD44 v6 displays CSC-like 
properties and is closely associated with PCa stemness (59).   
CD44 v6  predicts poor prognosis and is a marker of constitutive and 
reprogrammed CSCs driving colon cancer metastases (60). CD44 v3 
is a specific CSC marker of head and neck cancers (61;62). CD44 
v8-v10 is a gastric CSC marker and its expression is low in normal 
tissues thus making it an ideal target to eliminate gastric CSCs (63). 
Moreover, CD44 v8-v10 contributes to ROS defense by promoting 
the sintesis of reduced glutathione (GSH). These findings reveal a 
role for CD44 v8-v10 in the protection of CSCs from high levels of 
ROS and gastric tumor growth (64).   
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In addition to CD44 v8-v10 transmembrane expression, its 
enzymatic cleavage has also been investigated. The cleaved 
fragment, detected by presence of the soluble extracellular domain 
in ascites fluid of ovarian cancer patients, correlated with worse 
prognosis (65). However, the prognostic value of CD44s and CD44v 
isoforms seems to vary by cancer type and discrepancies or 
controversial results have been reported even within the same tumor 
type. The contradictory conclusions, regarding the correlation 
between CD44 expression and disease prognosis, may be caused by 
using different  methodologies  (66). Then commercially available 
CD44 assay kits containing well-characterized CD44s and CD44v 
antibodies with standardized protocols are crucial for comparison 
among different studies to come to general conclusions.  
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1.6  Toll-Like receptors: properties and functions in health and 
disease   
 
Toll-Like receptors (TLRs) are a family of transmembrane proteins 
that recognize pathogen associated molecular patterns (PAMPS), 
molecules highly conserved in bacteria, viruses, fungi and parasites 
(67). 
TLRs are expressed in epithelial and immune cells. Ligand 
activation of TLRs initiates the onset of inflammation (68) by either 
MyD88-dependent pathways, that culminate with the induction of 
inflammatory cytokines through MAPKs and NF-kB activation, or 
TRIF-dependent pathways, which are responsible for the induction 
of inflammatory cytokines as well as type I interferons by IRF-3 
activation (69).  
To date, 10 isoforms have been identified in humans: TLR 1, 2, 4, 5 
and 6 are expressed at the cell surface membrane and recognize 
pathogens-derived lipids, lipopolysaccharides, peptidoglycan or 
proteins. In contrast, TLR 3, 7, 8 and 9 recognize (poly) nucleotides 
in endolysosomes (70) (Figure V).   
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 Nat Rev Immunol. (2013) 13 (6): 453–60 
Figure V. Toll-Like receptors signalling.  
TLRs bind to their respective ligands at the cell surface (TLR 1,TLR 2,TLR 4, 
TLR 5, TLR 6) whereas TLR3, TLR7–TLR8, TLR9 and TLR13 sense viral and 
microbial nucleic acids at the endosomal compartment.  
Ligand-induced dimerization of receptors is followed by engagement of TIR 
domain-containing adaptor proteins (either MYD88, MAL, or TRIF and TRAM) 
that stimulates downstream signalling pathways leading to the activation of the 
mitogen-activated protein kinases (MAPKs), JUN N-terminal kinase (JNK) and 
p38. Subsequently, the activation of transcription factors such as nuclear factor-
κB (NF-κB) and the interferon-regulatory factors (IRFs) induce pro-inflammatory 
cytokines, and in the case of the endosomal TLRs, type I interferon (IFN).  
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TLRs are the key sensors of the innate immunity, mediated by 
cytokine and chemokine secretion, and are critically involved in 
priming the adaptive immune response necessary for killing 
invading pathogens (71) thus a negative regulation of their 
signalling is crucial to prevent over-activation of the immune system 
resulting in chronic inflammatory diseases and autoimmune 
disorders (72). 
Besides the canonical antimicrobial function of TLRs, it has been 
demonstrated that functional TLRs are also expressed on a wide 
variety of tumors playing a crucial role in tumor growth and 
progression. Their expression is deregulated in cancerous epithelial 
tissues (73).  
The role of TLRs in cancer is controversial: it has been demonstrated  
both an anti-apoptotic effect (protumoral) and a pro-apoptotic 
function (antitumoral) for several TLRs.   
The immune system has the potential to either promote tumor 
progression as well as mediate tumor destruction. Which of these 
conditions prevails depends on the balance between the protumor 
and antitumor mediators of both innate and adaptive immunity. 
Chronic inflammation is involved in polarizing immunity toward a 
tumor-promoting phenotype producing an immune suppressive 
environment that is permissive for carcinogenesis. Conversely, 
acute inflammation promotes a tumor-rejecting response (74). 
It was suggested that TLR gene polymorphisms might alter TLR 
signaling, thus affecting inflammation and prostate cancer risk. 
Sequence variants of TLR1, TLR6 and TLR10 were confirmed to 
increase prostate cancer risk (75)  as well as variants of TLR4 (76). 
However, controversial results were also obtained (77). 
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1.7  The dual role of Toll-Like receptor 3 in cancer  
Although conflicting reports have been published concerning the 
pro or antitumoral role of several TLRs, most literature data agree 
on an antitumor role for TLR3 (78;79). In fact, the TLR3 ligand 
Ampligen has been proposed as a potentially safe immune-adjuvant 
in cancer therapy (80). The activation of TLR3 by the specific 
agonist polyinosinic:polycytidylic acid [poly (I:C)], a synthetic 
dsRNA analogue, exerts an antitumoral effect by inducing apoptosis 
with higher efficiency in the androgen-dependent prostate tumor cell 
line LNCaP than in the androgen-independent cell line PC3 
depending on differential degree of up-regulation of hypoxia 
inducible factor-1 (6). Furthermore, poly (I:C) stimulation recruits 
an antitumoral immune response. 
Galli R. and coworkers have previously demonstrated that activation 
of TLR3 in PCa cell lines induces the secretion of cytokines and 
chemokines that can recruit and activate immune cells in the tumor 
site promoting their anticancer activity (81).
Different hypothetic models of action for TLR3-dependent 
anticancer mechanism have been proposed (82): an immune-
mediated tumour growth suppression (83), a direct apoptotic effect 
on TLR3 expressing cancer cells (4;84-86) and an inhibition of 
tumor growth through both immune-mediated anticancer 
mechanisms and cancer cell apoptosis.  
Although the majority of studies have reported that TLR3 activation 
leads to tumor suppression, it has also been described to promote 
tumor development by enhancing cancer cell proliferation and 
survival (87). Increased TLR3 expression in patients with breast 
cancer was correlated with poor prognosis (88). The same author, 1 
year later, showed that 85% of the examined PCa cases were 
positive for TLR3 expression and that high levels of TLR3 were 
associated with biochemical recurrence (89). Furthermore, the 
outcomes of clinical trials using TLRs agonists are in general 
inconsistent (90). This extremely intricated context reflects our 
insufficient understanding of the direct role of TLR3 in cancer cells, 
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in particular cancer stem cells (CSCs), capable of initiating new 
tumors in vivo and interconvertible between a stem and non-stem-
cell state.  
CSC plasticity has been linked to inflammation which may select 
for, or induce, stem-like cell even if the underlying mechanisms 
remain poorly understood. 
Although the stimulation of TLR3 with poly (I:C) induces the death 
of particular subpopulations of tumor cells blocking tumor growth 
initially, it promotes breast cancer cells toward a CSC phenotype 
through the proliferation of CSCs together with the induction of a 
CSC phenotype from non-CSCs. Inhibition of both β-catenin and 
NF-kB is an effective strategy to control the growth of human breast 
cancer induced by TLR3 activation (7). This study suggest that the 
therapeutic potential of a given TLR agonist should be carefully 
evaluated with consideration of its possible role in mediating CSC 
phenotypes and potentiating more robust cancer recurrences. 
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2. AIMS
In the past years, much progress has been made towards better 
understanding the development and progression of PCa as well as 
the factors which drive the development of androgen independence. 
However, the highly heterogeneous nature of prostate cancer poses 
many obstacles to therapy.  
Several groups have proposed that NE cells may be resistant to 
hormonal therapy and therefore responsible for tumor recurrence 
following androgen ablation. In addition, the selective expression of 
the putative prostate cancer stem cell marker CD44 in NE tumor 
cells of PCa further supports the importance of such cells in therapy 
resistance and tumor recurrence and raises interesting questions 
about the relationship of the NE tumor cells to the elusive PCa stem 
cells. Our laboratory group has previously demonstrated that the 
TLR3 agonist poly (I:C) induces apoptosis in the androgen-
dependent tumor cell line LNCaP negative for neuroendocrine 
markers and CD44, while the androgen-independent cell lines PC3 
and DU-145 are nearly resistant to poly (I:C) treatment and share 
NE features associated with the expression of the stem/progenitor 
cell marker CD44(3). Thus, we called into question the existence of 
a subpopulation negative for neuroendocrine markers more prone to 
poly (I:C)-induced apoptosis. My PhD project aimed to evaluate 
whether the apoptosis resistance to poly (I:C) of the androgen-
independent PCa cell lines can be correlated to CD44 expression. 
To test if poly (I:C) targets or selects CD44high population, the 
modulation of membrane-CD44 protein in PC3 cells after poly (I:C) 
treatment was assessed by flow cytometry. The unexpected 
enrichment, following poly (I:C) treatment, of a CD44-negative 
population very small in size besides a CD44high cell subpopulation 
selection, led us to investigate the biological properties of 
CD44-negative and CD44high cell  subpopulations, resistant 
to poly (I:C), and in parental PC3 and DU-145 cells by 
FACS sorting. Therefore, we aimed to determine whether the 
cell populations generated by CD44-negative and CD44high sorted 
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cells were functionally distinct, in particular if CD44-negative 
sorted cells could be considered “stem-like cells” giving rise to 
CD44high cells, described to be stem-like and more tumorigenic in 
prostate cancer. To this purpose, we used in vitro gold standard 
functional method, the colony forming assay, to determine whether 
it enriches for a holoclone phenotype in the PC3 cells verifying the 
holoclone peculiar ability to regenerate the full spectrum of clonal 
heterogeneities. Moreover, we proposed to examine CD44 
expression in different clone types from primary clonogenic assay 
and to perform secondary clonogenic assay of these clones in order 
to compare the clone forming ability of the clones generated by 
CD44-negative cells and the clones derived by CD44high cells. The 
secondary clonogenic assay will be performed also on expanded two 
sorted subpopulations since they reflect the behavior of the single 
derived clones.  
Finally, CD44v isoforms have been identified as CSC markers and 
critical players in regulating tumor progression metastases and 
treatment resistance in many cancers (64;65). Thus, we aimed to 
investigate if the cell populations generated by CD44-negative and 
CD44high sorted cells expressed different CD44 splice variant 
isoforms at the mRNA and protein level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chiara Di Stefano 
29 
3. RESULTS
3.1 Poly (I:C) treatment selects highly expressing CD44 and 
CD44-negative subpopulations. 
We have previously demonstrated that the androgen-independent 
cell line PC3 is largely resistant to poly (I:C) treatment (6). To 
establish whether such incomplete  resistance can be possibly 
correlated to differences in CD44 expression, we treated PC3 cells 
with 25 µg/ml poly (I:C) for increasing times up to 4 days and 
analyzed the composition of the cell population by flow cytometry 
using an anti-CD44 antibody that recognizes both standard and all 
CD44 isoforms. We observed that poly (I:C) treatment  resulted in 
an increased percentage of CD44-negative population (only, 2-4% 
in control sample) up about 10-fold in 3 days treatment (Figure 1 
A) and a decrease of CD44-positive cells, accompanied by a shift to
a median fluorescence intensity (MFI) higher than the control 
(Figure 1 B and 1 C). The population lacking CD44 protein was 
very small in size : ~ 60% of these cells were < 7 µm, ~ 30% ranged 
from 7-15 µm and only 10% of CD44 negative cells were  > 15 µm 
(data not shown). 
Chiara Di Stefano 
30 
Figure 1. Modulation of CD44 expression following poly (I:C) treatment. 
CD44 expression was evaluated in PC3 cells after treatment with poly (I:C) for 2, 
3 and 4 days. Poly (I:C) stimulation enriches for CD44-negative cell 
subpopulation (A) while reduces the percentage of CD44+ cells (B) at the 
indicated times. CD44 expression was calculated as percentage of total live cells. 
Each data point is the mean ± SEM of three independent experiments *p < 0.05; 
**p < 0.01, ***p < 0.001, Student’s paired t-test. (C) Representative flow 
cytometry overlay of gated live cells before (dotted histogram) and following 72 
hours poly (I:C) treatment (black histogram) show an increase of CD44-negative 
cells (marker M1) and a decrease of CD44-positive population (marker M2). The 
grey histogram represents the isotype control APC-labeled IgG2B. Cells were 
gated using sytox blue stain to exclude dead cells 
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Most of the CD44-negative-enriched population resulting from  poly 
(I:C) treatment is included in a size area generally comprising the 
debris in flow cytometry analysis based on forward scatter vs side 
scatter. Thus, to verify our data excluding debris, we used PC3 cells 
infected with TWEEN-EGFP lentiviral vector and sorted only the 
GFP+ cell population. We treated the PC3 GFP+ cells with poly 
(I:C) or with the standard therapeutic agent docetaxel for 72 hours 
and again flow cytometry analysis confirmed the high increment of 
CD44-negative population after poly (I:C) stimulation (Figure 2 A). 
The representative dot plot (Figure 2 B), highlights  that the CD44-
negative/ GFP+ population enriched by poly (I:C) treatment derives 
from the very small size GFPlow population cells (0.4% CD44-
GFPlow cells in CTR vs 8.2% in poly (I:C)-treated cells). In fact, by 
gating exclusively the GFPlow cells we observed a much higher 
percentage of CD44-negative cells after poly (I:C), and, at a lesser 
extent, docetaxel stimulation (Figure 2 C). 
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Figure 2. Modulation of CD44 expression in PC3 GFP+ cells after poly (I:C) 
and docetaxel treatment. 
PC3 GFP+ sorted cells were treated with 25 µg/ml poly (I:C) and with 20 nM 
docetaxel for 72 hours. Both treatments select for CD44-negative cells (A). The 
representative FACS plots (B) show a dramatic increase of CD44-negative GFPlow 
cells after poly (I:C). If only GFPlow cells are considered, a remarkable increase 
of CD44-negative subpopulation following poly (I:C) and docetaxel treatment is 
observed (C). Data represent the mean ± SEM derived from three independent 
experiments *p < 0.05; **p < 0.01; ***p < 0.001, Student’s paired t-test. 
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3.2 Poly (I:C)-enriched CD44-negative cells give rise to CD44-
positive cells  
In order to explore the biological properties of the cell populations 
enriched after poly (I:C) treatment, single PC3 GFP+ cell 
suspensions were obtained and sorted by FACS into CD44high and 
CD44-negative cells. The purity of these cell populations was 
generally >95% as revealed by post-sort analysis (not shown). 
Surprisingly, 48 hours after sorting, CD44-negative GFP+ cells gave 
rise to a population expressing membrane-CD44 protein. Data in 
Figure 3 shows that 75% of the cells generated by CD44-negative 
sorted population become positive for CD44. 
Figure 3. CD44 expression in CD44-negative and CD44high -sorted cells 
resistant to poly (I:C) stimulation. 
Percentage of CD44+ cells in CD44-negative GFP+ and CD44high GFP+ sorted 
PC3 populations, resistant to 72 hours poly (I:C) treatment, immediately after 
sorting (0 d) and 48 hours (2d) after culturing. n=3 mean ± S.E.M **p < 0.01, 
Student’s paired t-test.  
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3.3 CD44-negative cells sorted from parental PC3 and DU-145 
bulk populations spontaneously convert to highly positive CD44 
cells 
We next explored whether the minority CD44-negative population 
present in parental PC3 and DU-145 cell lines could also undergo 
spontaneous conversion. To this aim, we isolated pure (average, 
>95%) populations of CD44high and CD44-negative cells 
fractionated by FACS directly from PC3 and DU-145 cultures. Cells 
from these two PC3 subpopulations were seeded into 24-well plates 
immediately following cell sorting and monitored for CD44 
expression over the subsequent 11 days. Purified CD44high cells 
remained a pure CD44high population, whereas CD44-negative cells 
gave rise to a CD44-positive cell population that progressively 
increased, restoring the initial CD44 expression profile in 11 days 
(Figure 4 A). CD44high cells represent ~ 4% of CD44-negative 
fraction collected immediately after sorting (0 d), whereas their 
percentage increases in culture to ~ 60% in 24 hours. The 
representative FACS analysis of CD44 expression in the time-
course experiments represented in Figure 4 B shows that CD44-
negative cells acquired CD44 expression on their surface in just 24 
hours post-sorting and that this expression reached higher levels 
after 2, 6 and 11 days in vitro expansion. Of note, cell counts 
revealed that, in the first 24 hours post sorting, no cell proliferation 
occurred, since the number of cells plated remained constant. 
In addition, similar FACS experiments were performed on DU-145 
cells to test whether the fast conversion from CD44-negative to 
CD44high cells was shared by another androgen-insensitive PCa cell 
line. As shown in Figure 4 C, CD44-negative subpopulation sorted 
from DU-145 spontaneously converted into CD44high, even with 
higher efficiency than PC3 cells. 
. 
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Figure 4. Time course of CD44 expression in CD44-negative and CD44high -
sorted cells. 
Percentage of CD44+ cells in CD44-negative and CD44high -sorted PC3 
populations immediately after sorting (0 d) and at the indicated times after 
culturing (A). n=3 mean ± S.E.M **p < 0.01, Student’s paired t-test.  
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(B) Representative histograms of CD44 expression at the indicated time points of 
culturing CD44-negative and CD44high cell populations. The dotted histogram 
represents the isotype control APC-labeled IgG2B, the black histogram indicates 
APC-labeled CD44 antibody staining.  
(C) Percentage of CD44-positive cells in CD44-negative and CD44high -sorted 
DU-145 populations immediately after sorting (0 d), 24 and 48 hours after in vitro 
expansion. n=3 mean ± S.E.M ***p < 0.001, Student’s paired t-test. 
 
 
3.4 Cells derived from CD44-negative subpopulation show 
higher clonogenic potential than cells derived from CD44high 
population producing mainly holoclones  
 
Our results obtained by sorting experiments suggest that CD44high 
cells, described to be stem-like and more tumorigenic in prostate 
cancer (39), may arise from components of the CD44-negative 
population. Therefore, in order to investigate and compare the 
functional properties of CD44-negative and CD44high cells, we 
evaluated their respective clonogenic potential in limiting dilution 
assays. We plated these two PC3-sorted subpopulations at 1 cell per 
well in 96-well plates, one day after plating we selected those wells 
that contained only 1 viable cell and then we followed the 
development of each individual clone over the following two weeks. 
Although CD44-negative and CD44high cells showed a similar 
clonogenic potential in primary clonogenic assay (Figure 5A 0 d), 
28 days after sorting CD44-negative-derived cells exhibited a 
significantly higher clonogenic potential than those derived from 
CD44high cell population (Figure 5 A).  To investigate this delayed 
increase in clonogenic potential, we analyzed the clone types in 
primary clonogenic assay, since the formation of holoclones has 
been adopted as a surrogate stem cell assay, particularly in the study 
of prostate cancer (91). In primary clonogenic assay, 2 weeks after 
plating, 63% of clones generated by sorted CD44-negative cells 
developed into typical holoclones, whereas 22% were meroclones 
and 15% formed paraclones. Conversely, the clones derived by 
sorted CD44high cells were mostly meroclones (46%) and only 27% 
were represented by holoclones (Figure 5 B). As shown in Figure 
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5 C, the distinct morphologies of the three types of clones generated 
by CD44-negative and CD44high -sorted cells were easily identified 
at 2 weeks after single-cell plating. Holoclones contained tightly 
packed small cells and paraclones larger and fewer cells, whereas 
meroclones consisted of cells of intermediate sizes and amount, as 
defined (43). 
Figure 5. Clonogenic potential and clonal heterogeneity of CD44-negative 
and CD44high -sorted cells.  
(A) In the limiting dilution assay, immediately after cell sorting (0 d), there are no 
statistical differences in clonogenic potential among CD44-negative (CD44-) and 
CD44high -sorted populations. The clonogenic assay performed on expanded two 
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sorted subpopulations (cultured for 28 days) shows a significantly higher 
capability to form clones of CD44 negative-derived cultured cells than CD44high -
derived cells (*p < 0.05). The CD44-negative-sorted cells produced mainly 
holoclones whereas CD44high -sorted population gave rise principally to 
meroclones (B). All the data were analyzed by Student’s paired t-test. n=3 mean 
± S.E.M. The phase contrast representative images of the different types of clones 
generated by CD44-negative and CD44high -sorted cells are shown in (C).  
 
 
3.5 Clones derived from CD44-negative cells show a greater 
clonogenic potential than clones generated by sorted CD44high 
population in secondary clonogenic assay.  
 
We then wondered to examine CD44 expression in different clone 
types from primary clonogenic assay and to perform secondary 
clonogenic assay of these clones. To this aim, we randomly chose 
some clones derived from the primary clonogenic assay of sorted 
CD44-negative and CD44high PC3 subpopulations and evaluated 
CD44 expression after 30 days in vitro expansion of 12 CD44high -
derived clones (5 holoclones, 6 meroclones, and 1 paraclone) and 13 
CD44-negative-derived clones (10 holoclones, 1 meroclone and 2 
paraclones). All the clones became positive for CD44 expression as 
revealed by flow cytometric analysis (Figure 6 A). Furthermore, we 
verified the holoclone ability to regenerate the full spectrum of 
clonal heterogeneity selecting, in total, 7 holoclones and 3 
meroclones derived by CD44high and by CD44-negative primary 
clonogenic assay. In line with published evidence (44), holoclones, 
but not meroclones, gave rise to all three types of clones in the 
secondary clonogenic assay (Figure 6 B). Moreover, when serially 
in vitro, 17 CD44high and CD44-negative derived total holoclones 
and 14 meroclones, the holoclones showed an higher long-term 
propagation ability than meroclones (Figure 6 C). 
In order to compare the clone forming ability of the clones generated 
by CD44-negative cells and the clones derived by CD44high cells, we 
randomly selected and expanded 6 clones derived from CD44-
negative cells and 6 clones derived from CD44high cells and we 
carried out secondary clonogenic assay. As expected from holoclone 
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enrichment in CD44-negative-derived clones in primary clonogenic 
assay, we observed a significantly higher clonogenic potential in the 
clones generated by cells derived from CD44-negative population 
than in those derived from sorted CD44high  population (Figure 6 D).
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Figure 6. CD44 expression, proliferative and self-renewing capacities of 
CD44-negative and CD44high -derived clones.  
(A) Percentage of cells expressing CD44 protein in PC3 bulk population and in 
CD44-negative and CD44high derived clones 30 days after cell sorting.  
(B) Clone classification, following secondary clonogenic assay, of CD44-
negative and CD44high -derived primary holoclones (n=7) and meroclones (n=3).  
(C) Percentage of clone survival during 120 days follow-up period.  
By 120 days, most holoclones proliferated robustly (88,2%) and only 2 holoclones 
aborted. 7 of the 14 meroclones (50%) were abolished and could not be further 
propagated. 
(D) The clones generated by CD44-negative cells showed an higher clonogenic 
potential than CD44high -derived clones (**p < 0.01). The table indicates the 
number of wells that developed 1 clone starting from 1 single viable cell for 
CD44-negative and CD44high –derived clones (n=6 for each group). The data were 
analyzed by chi-square test. 
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3.6 CD44-negative-derived population specifically re-expresses 
CD44 v8-10 splice variant isoform 
Our data indicate that the cellular population generated by CD44-
negative-sorted cells after 2 days in culture was almost 
indistinguishable from the CD44high -derived cells in terms of CD44 
expression (Figure 4). In addition, both the CD44high and CD44-
negative-derived clones become positive for CD44 as revealed by 
using an anti-CD44 antibody that recognizes a common epitope to 
CD44 standard (CD44s) and all CD44 variant (CD44v) isoforms. 
However, the variant isoforms (CD44v) have been linked to 
subpopulations endowed with stem cell potential, to enhanced 
metastatic potential and a poor prognosis in several types of cancer 
(60;91).  
Therefore, we aimed to investigate if the functionally distinct cell 
populations generated by CD44-negative and CD44high cells 
expressed different CD44 splice variant isoforms at the mRNA and 
protein level. We first determined the expression of CD44 isoforms 
in PC3 cells by designing PCR primers in constant exons 5 and 15, 
flanking the variable region of the CD44 gene (Figure 7 A). 
Semiquantitative RT-PCR analysis from PC3 cells revealed the 
presence of three main products at a size of 396, 600 and 792-bp, 
whose sequences correspond to CD44s, CD44 v10 and CD44 v8-
v10 isoforms, respectively. Subsequently, we performed RT- PCR 
from both PC3 and DU-145 CD44-negative and CD44high -derived 
cells 14 and 28 days after cell sorting and we found that CD44 
transcript variant 3, containing variant exons v8–v10, was more 
highly expressed in the population generated by CD44-negative-
sorted cells (data not shown). In order to evaluate the CD44 v8-v10 
levels in the two sorted subpopulations, we performed splice 
isoform-specific quantitative RT-PCR (qRT-PCR) analysis by 
designing specific primers inside CD44 v8-v10 exons. Our results 
show a twenty-fold higher expression of CD44 v8-v10 mRNA in 
PC3 CD44-negative-derived cells compared to CD44high -derived 
population 21 days after sorting (Figure 7 B). We next used an 
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antibody specific to CD44 v8-v10 to prove the differential 
expression of this splice variant at the protein level. About 80% of 
CD44-negative derived cell population was positive for CD44 v8-
v10 membrane protein, while only 2% of CD44high-derived cells 
expressed this CD44 splice variant isoform (Figure 7 B). 
An enriched  expression of CD44 v8-v10 transcript was also 
observed in CD44-negative-derived DU-145 cells, although at less 
extent (Figure 7 C). Data obtained on membrane CD44 v8-v10 
protein level mirrored that on CD44 v8-v10 mRNA (Figure 7 C). 
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Figure 7. CD44 v8-v10 expression in CD44-negative and CD44high -derived 
cell sorted populations. 
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(A) Total RNA isolated from PC3 cell line was subjected to RT-PCR analysis 
with primers targeted to exons 5 and 15 of human CD44 cDNA. Three main PCR 
products derived from CD44 v8-v10 (792 bp), CD44 v10 (600 bp) and CD44s 
(396 bp) are indicated. 
(B) CD44 v8-v10 specific qRT-PCR analysis showed an higher expression of 
CD44 v8-v10 mRNA in PC3 cells derived from CD44-negative cell population 
compared to those derived from CD44high cell population 21 days after sorting.  
PC3 CD44-negative-derived cells express 82% and 77% of CD44 v8-v10 
membrane protein 14 and 21 days after culturing, respectively.  
(C) DU-145 CD44-negative-derived cell populations express higher levels of 
CD44 v8-v10 transcript and membrane protein than CD44high -derived cells 14 
and 28 days after sorting. Data are shown as fold increase of CD44 v8-v10 positive 
cells in CD44-negative-derived cells (at the mRNA and protein level) compared 
to CD44high -derived cells (adjusted to 1). All the data were analyzed by Student’s 
paired t-test. n=3 mean ± S.E.M.  *p < 0.05; **p < 0.01. 
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4. DISCUSSION
So far, the effect of poly (I:C) treatment has been evaluated on the 
overall cell population and the possible presence of sub-populations 
with different sensitivity to poly (I:C) has not yet been explored. 
Therefore, we have started investigating if apoptosis following poly 
(I:C) stimulation takes place only in specific sub-populations of 
androgen-independent prostate cancer cell lines first of all 
evaluating if the apoptosis resistance to poly (I:C) treatment can be 
linked to CD44 expression, given that CD44 has been proven to be 
a candidate marker for normal prostatic epithelium stem cells and 
prostate cancer stem cells (92).  
Unexpectedly, our experimental evidence showed that poly (I:C) 
treatment enriched for a CD44-negative population very small in 
size besides a CD44 highly positive population. Moreover, an 
enrichment of CD44-negative cell subpopulation was observed also 
following docetaxel, the standard chemotherapeutical treatment of 
PCa. Mounting evidence suggests that CSCs may be enriched 
following anti-cancer therapeutics (93;94) that lead to the selection 
of even more aggressive cells, possibly because they hit mostly the 
bulk tumor mass without impacting the stem compartment thus 
producing only temporary success followed by a relapse. 
Patralawa and coworkers obtained CD44high and CD44-negative 
tumor cell populations from multiple PCa cell cultures and xenograft 
such as PC3 cell line showing that CD44 high PCa cells are more 
proliferative, clonogenic, tumorigenic, and metastatic than the 
isogenic CD44-negative PCa cells (39). On the other hand, they also 
observed tumor development in CD44-negative PCa cells and the 
emergence of CD44-positive clones from a pure CD44-negative cell 
population. The authors explained the tumorigenicity of the CD44-
negative PCa cells as a possible contamination from CD44-positive 
cells or as the ability of a minor subset of cells, in the CD44-negative 
population, to develop into CD44-positive cells. Our results are 
partially in accordance with this latter explanation because we 
demonstrated that both CD44-negative-sorted cells, resistant to poly 
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(I:C), and CD44-negative cells from parental PC3 and DU-145 
spontaneously converted to highly positive CD44 cells, known to be 
stem-like cells in PCa. Nevertheless, we sorted a CD44-negative 
population very small in size, usually excluded when gating cells on 
the basis of Forward Scatter / Side Scatter. In contrast, the negative 
population selected by Patralawa and colleagues represented the 
bottom 5% most dimly stained (CD44low), whereas for the positive 
ones, only the top 10% most brightly stained (CD44high) was 
considered. In fact the Authors observed CD44 expression in 100% 
of PC3 cells. Thus, we believe that both in PC3 and DU-145 cells 
there is an highly dynamic and fast-converting CD44-negative 
population that express CD44 protein as soon as 24 hours after cell 
sorting. This conversion has been observed in other systems. Qian 
H and colleagues showed that primary mesenchymal stem cells 
(MSCs) of bone marrow reside in the CD44-negative cell fraction 
that rapidly converts into a CD44 positive phenotype (95). 
Moreover, a cell population negative for CD44 expression with 
stem-cell like traits has been identified in head and neck squamous 
carcinoma as well (96). 
In addition, evidence for tumor cell populations that can reversibly 
shift between stem-like and more committed cells, is emerging. It 
has been demonstrated that a subpopulation of basal-like human 
mammary epithelial CD44low cells spontaneously dedifferentiated 
into CD44high stem-like cells. Moreover, oncogenic transformation 
enhanced the spontaneous conversion, so that non-stem cancer cells 
gave rise to CSC-like cells in vitro and in vivo (97). However, the 
Authors  show that CD44low cells converted into the CD44high state 
at an highest rate displayed minimal interconversion ability (up to 
10%), whereas we observed a dramatic high rate of conversion in 
the small size CD44-negative- sorted population. Furthermore, 
clonal analysis assay revealed that all the clones produced by CD44-
negative-sorted cells become as positive for CD44 as the CD44high -
sorted population. Chaffer and colleagues showed that the tumors 
arising from purified CD44low cells contained a small fraction of 
CD44high cells (2–22% of the tumor cells). In our study, we did not 
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purify CD44low cells but a population completely lacking CD44-
membrane protein. Lentiviral infection experiments, by using an 
EGFP expression vector, allow us to identify and sort a CD44-
negative cell population characterized by small size.  
Then, to determine whether the cell populations generated by CD44-
negative and CD44high -sorted cells were functionally distinct, in 
particular if CD44-negative-sorted cells could be considered “stem-
like cells” giving rise to CD44high cells, we used the holoclone 
formation assay, adopted as a surrogate stem cell assay, particularly 
in prostate cancer (98). This assay circumvent the isolation of CSCs 
by using cell surface markers that are often subjected to dynamic 
expression changes. We found that CD44-negative-derived cells 
showed an higher clonogenic potential than CD44high -derived cell 
population producing mainly holoclones. The primary clones, 
generated by CD44-negative cells and subjected to secondary 
clonogenic assay, exhibited a greater clonogenic potential than the 
clones produced by CD44high -sorted cells as well. According to 
evidence reported in literature (44), holoclones expressed high 
levels of CD44, sustained in vitro long-term propagation and gave 
rise to all three types of clones regenerating the clonal heterogeneity 
in secondary clonogenic assay. Unlike Li H and colleagues, we did 
not observe differences in CD44 expression among holoclones, 
meroclones and paraclones, suggesting that this molecule is 
probably expressed in both cancer stem, progenitor and more 
differentiated cells. Our data suggest that CD44high -derived cell 
population contains a smaller proportion of self -renewing 
cells than CD44-negative-derived cells.  
Although CD44 has been identified as CSC marker in several 
cancers (99), its ubiquitous expression in many cell types has limited 
its use in targeting CSCs. Furthermore, conflicting data implicate 
CD44 in both tumor suppression and progression (63;100;101), 
largely attributed to the expression of alternatively spliced variants. 
In this thesis, we show that the transcript of a CD44 variant 
containing variable exons 8, 9, and 10, called CD44 variant 3 or 
CD44 v8-v10, as well as CD44 v8-v10 protein were significantly 
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elevated in CD44-negative-derived cells compared with CD44high -
generated population. CD44 v8-v10 was first described in colon 
cancer and was found to be upregulated in primary and metastatic 
tumors but rarely expressed in normal mucosa of adults and to 
promote metastasis in colon (102) pancreatic and breast cancer cells 
(103;104). Moreover CD44 v8-v10 is a gastric CSC marker having 
a low expression in normal tissues thus it is considered an ideal 
target to eliminate gastric CSCs (63). 
Notably, there is evidence that CD44 v8-v10 enhances the CSC-like 
characteristics also in prostate cancer. Stress-response protein 
RBM3 was shown to impair the splicing of CD44 v8-v10 and 
consequently increase the expression of its standard isoform 
attenuating the stem-like properties of prostate cancer cells. When 
cells experience stress, RBM3 is down-regulated with an increase of 
CD44 v8-v10 that enhances the CSC-like characteristics in prostate 
cancer cells (105). 
CD44 v8-v10 may also be responsible for conferring resistance to 
therapeutic treatment stabilizing the cystine transporter xCT, 
thereby promoting the ability of cancer cells to defend themselves 
against reactive oxygen (64).  
In conclusion, we have shown that CD44 v8-v10 is the major variant 
found in the stem-like CD44-negative-derived population. 
Finally, our data could provide new insights about the role of TLR3 
stimulation in tumors. Although the majority of studies by us and 
other groups have reported that TLR3 activation leads to tumor 
suppression, it has also been described to promote breast cancer cells 
toward a CSC phenotype through the proliferation of CSCs together 
with the induction of a CSC phenotype from non-CSCs (7). 
Future work will elucidate if the higher clonogenic ability observed 
in CD44-negative-derived population may be specifically imputed 
to CD44 v8-v10 splice isoform and if may also be responsible to 
therapeutic treatment resistance. Given that many CD44v isoforms 
are preferentially expressed on cancer cells and involved in tumor 
progression, CD44v isoforms might be better CSC markers than 
CD44s isoform. The identification of new CD44v isoforms in CSCs 
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will open new field of investigation to find innovative targeted 
therapies against CSCs. 
Finally, we know that the CD44 v8-v10 enriched population arise 
from a small in size cell population lacking CD44 expression. Thus, 
a specific characterization of CD44-negative stem-like cells will 
open new field of investigation to find innovative therapies that 
selectively target the putative stem-like subpopulation involved in 
therapy resistance and tumor relapse. 
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5. MATERIALS AND METHODS
5.1 Cell lines 
PC3 (Lot: 61777391) and DU-145 (Lot: 59722255) cells were 
obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and cultured respectively in RPMI-1640 and 
Minimum Essential Eagle Medium (Sigma, Saint Louis, MO, USA) 
supplemented with 2 mM L-glutamine (Sigma), 200 U/ml 
penicillin–streptomycin (Sigma), sodium pyruvate 1 mM (Sigma), 
Hepes 10 mM (Sigma) and 10% fetal bovine serum (FBS) (Life 
Technologies-Gibco Eugene, OR, USA). They were mantained at 
37°C in a humidified 5% CO2 incubator. For all the experiments, 
prostate cancer cell lines were stimulated with poly (I:C) High 
Molecular Weight (InvivoGen, San Diego, CA) and docetaxel 
(Sigma) in 3% FBS medium. 
5.2 Flow cytometry 
Cells were detached with trypsin (0.25%)/ EDTA (Sigma), washed 
with PBS and incubated with APC-conjugated CD44 antibody (BD-
PharMingen, San Diego, CA, USA) and isotype control APC-
conjugated IgG2B (BD-PharMingen) in PBS BSA 1% (Sigma) for 
30 minutes on ice prior to flow cytometric analysis. Sytox Blue 
Dead Cell Stain (Life Technologies, Eugene, OR, USA) was added 
to exclude dead cells. For CD44 v8-v10 staining 1x105 cells were 
incubated with 3 µg/ml Anti-human CD44 v9 primary antibody 
(clone: RV3) (Cosmo Bio Co.Ltd, Tokyo, Japan) in PBS 0.2 % BSA 
for 45 minutes at 4°C. Cells were then washed twice in PBS BSA 
0.1 % and incubated with the secondary antibody APC-labeled Goat 
anti-Rat IgG (H+L) (Invitrogen, Carlsbad, CA, USA) diluted 1:200 
in PBS BSA 0.1 % for 30 minutes at 4 °C in the dark. Finally, the 
cells were washed two times in PBS BSA 0.1 % and resuspended in 
300 µl PBS containing 0.5 µg/sample Sytox Blue Dead Cell Stain in 
5 ml FACS tubes. Cells were assayed using aCyAn ADP flow 
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cytometer (Beckman Coulter, Brea, CA, USA) and data were 
analyzed employing FCS5 express Software (De Novo Software).  
 
5.3 Fluorescence-activated cell sorting (FACS) analysis 
 
For sorting experiments, the PC3 and DU-145 cells were stained 
with APC-conjugated CD44 antibody (BD-PharMingen, San Diego, 
CA, USA) and were sorted into RPMI medium whereas DU-145 
cells into Minimum Essential Eagle Medium. Cell populations were 
analyzed post-sorting to ensure purity of sorting before progressing 
with additional experiments. Apoptotic cells were excluded during 
FACS by elimination of cells positive for staining with Fixable 
Viability Stain 780 (FSV780) (BD Biosciences, San Jose, CA, 
USA). FACS was performed with a FACSAria Cell Sorter (BD 
Biosciences, Tokyo, Japan). 
 
5.4 Single-cell cloning by limiting dilution 
 
CD44high and CD44-negative-sorted cells were resuspended in fresh 
medium to generate a single-cell suspension with a density of 10 
cells/mL. Then, 100 μL single-cell suspension was dispensed into 
each well in a 96-well culture plate. After plating, we selected only 
the wells that contained 1 viable cell excluding the wells with no 
cells or with more than one cell. These single-cell wells were  
maintained in 10% FBS medium and were checked 14 days after 
cell sorting experiment to establish clonogenic potential. The 
resulting colonies were graded on their morphology and ability of 
cells from these colonies to proliferate and differentiate. When the 
colonies grew confluent, they were expanded in order to perform 
further experiments on the CD44-negative and CD44high -derived 
clones.  
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5.5 Establishment of GFP-tagged PC3 cells 
Briefly, 293T human renal epithelial packaging cells were 
transfected with TWEEN-EGFP lentiviral vector together with the 
packaging plasmids using calcium phosphate trasfection. Virus-
containing medium was collected after 72 h, centrifuged at 18000 
rpm and then passed through a 0.45 µm filter to remove debris. PC3 
cells were then infected with the virus-containing supernatant 
filtered and 10 µg/µl polybrene overnight. 
5.6 RNA isolation, RT-PCR and qRT-PCR  
Total RNA was extracted using TRIzol reagent (Invitrogen) and 
reverse transcription was performed with High-Capacity RNA-to-
cDNATM Kit (Applied Biosystems-Thermo Fisher ,Waltham, MA, 
USA). 
The expression profiling of CD44 isoforms in PC3 and DU cells 
was analysed by semiquantitative RT-PCR using the following 
primers 5’GCAGCACTTCAGGAGGTTAC3’and 
5’GCTCCATTGCCACTGTTGAT3’and gene expression levels 
were normalized to beta actin  
(5’-CTACAATGAGGTGCGTGTGTGG-3’ and  
5’-CGGTGAGCATCTTCATGAGG-3’). 
The expression levels of CD44 variant 3 were determined by Sybr 
Green QPCR (Bioline, Taunton, MA, USA) performed on cDNA 
using the StepOnePlus™ Real-Time PCR System (ThermoFisher). 
Data were analyzed by the ΔΔCt method and GAPDH was used to 
normalize the expression levels of mRNA.  
The primers used were as follows:  
CD44 variant 3: 5’-ATCCCAGACGAAGACAGTCC-3’ and 
5’-ACCTGTGTTTGGATTTGCAGT-3’;  
GAPDH: 5’-TGCACCACCAACAACTGCTTAG-3’ and 
5’-GAGGCAGGGATGATGTTC-3’. Each CD44 isoform has 
been related to its specific RefSeq mRNA (GeneID for CD44 variant 
3, NM_001001390). Clustal Omega software was used for multiple 
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sequence alignment before design specific primers by using Primer 
3 software. 
 
5.7 Statistical Analysis  
All experiments were repeated at least three times. All numerical 
data were described as mean ± SEM. Data were analyzed using the 
two-tailed student t-test. A probability value of 0.05 or less was 
considered significant.   
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